The years leading up to the financial crisis were like a dream for Don and Craig Hodges, the father-and-son money management team running Dallas mutual fund manager Hodges Capital. The family�� flagship Hodges Fund, founded in 1992 by father Don, was up 201% from 2003 to 2007 versus a 83% total return for the S&P 500. Hodges Fund had won five Lipper Awards��he equivalent of Oscars among mutual fund managers��or best multi-cap core fund. Assets poured in, swelling the fund from $50 million in 2002 to $750 million by the end of 2007.
Then the bottom dropped out of the market, and like other stock funds, Hodges fell hard, down 50% in 2008 versus 37% for the market.
��e didn�� see the liquidity part coming,��recalls Craig Hodges, the firm�� 50-year-old CEO and chief investment officer. ��ven though company fundamentals weren�� changing that fast, people were selling whatever they could.��/p>
General ugliness ensued as the family�� bread and butter business went into crisis mode.
5 Best Communications Equipment Stocks To Watch Right Now: Boulder Brands Inc (BDBD)
Boulder Brands, Inc., incorporated on May 31, 2005, is a supplier of gluten-free and health and wellness products in the United States and Canada. The Company distributes its products in all retail channels, including natural, grocery, club and mass merchandise. The Company also has a presence in the foodservice and industrial channels. The Company�� product portfolio consists of spreads, milk and other grocery products marketed under the Smart Balance, Earth Balance and Bestlife brands, and gluten-free products sold under the Udi's, Glutino and Gluten-Free Pantry brands. The Company operates in two segments: Smart Balance and Natural. The Smart Balance segment consists of its branded products in spreads, butter, grocery and milk. The Natural segment consists of its Earth Balance, Glutino and Udi's branded products. In December 2013, the Company announced that it has acquired 100% interests of Phil's Fresh Foods, LLC, owner of EVOL Foods (EVOL).
Smart Balance Products
The Smart Balance line of products is available in a range of categories, formats and sizes in the supermarket, mass merchandise and convenience store channels of distribution. Some of the Company�� buttery spreads are also available in bulk and individual serving formats for use in the industrial and foodservice channels. The Company�� Smart Balance buttery spreads are made from a patented blend of natural oils to help balance fats in the consumer's diet and to help improve the good-to-bad cholesterol ratio when used as part of the Smart Balance Food Plan. Smart Balance Spreadable Butters, available in original, light and extra virgin olive oil varieties, are a blend of creamery fresh butter and canola oil that contain less saturated fat than butter, as well as functional ingredients like EPA/DHA Omega-3 and plant sterols.
The Company offers a range of enhanced milk products, with different varieties containing EPA/DHA Omega-3s, plant sterols, and added levels of calcium and protein. The Comp! any use low and fat-free milks enhanced with non-fat milk solids to give the taste and texture of whole or reduced fat milk. The Company�� milk varieties include fat-free milk, 1% lowfat milk and lactose-free milk and are available in markets across the United States. The Company�� peanut butter products contain ALA Omega-3 from flax oil. The Company�� cooking oil and cooking sprays are designed for use in cooking, baking and salads to aid in avoiding trans fat and hydrogenated oils. The Company also markets a Smart Balance Buttery Burst Spray. The spray has zero calories, zero carbs and zero fats per serving and can be used as a pan spray or as a topping.
The Company�� Smart Balance Light Mayonnaise Dressing has half the fat of regular mayonnaise, is non-hydrogenated, contains zero grams of trans fat and contains natural plant sterols and ALA Omega-3. The Company created the Smart Balance Food Plan, incorporating many of its Smart Balance products, in order to help consumers achieve a healthy balance of natural fats in their daily diet. The plan includes menus, as well as numerous recipes.
Natural
The Earth Balance line of products offers a range of buttery spreads, sticks, soymilks, nut butters and vegan mayo dressings formulated for consumers interested in natural, plant based and organic products. Glutino offers a range of shelf stable and frozen gluten-free products, including snack foods, frozen baked goods, frozen entrees and baking mixes, throughout the United States and Canada. Glutino also offers a range of fresh breads under the Genius brand name. Based in Denver, Colorado, Udi's markets gluten-free products under the Udi's Gluten Free Foods brand in the retail market. The Company owns and operates a health and wellness, subscripton-based Website at www.thebestlife.com, which is based on the philosophies of Bob Greene.
The Company competes with Unilever, ConAgra Foods, Dean Foods, Land O' Lakes, Hain Celestial Group, Inc., Food for L! ife, Van'! s, Nature's Path, Mary's Gone Crackers, Enjoy Life, Pamela's Gluten Free, Rudi's Gluten-Free, French Meadow Bakery, Schar, Kinnikinnick, Amy's Gluten Free, Snyder's, Blue Diamond Gluten-Free, Bob's Red Mill Gluten-Free and Food Should Taste Good.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Hain have gained 2.2% to $79.91 today at 11:13 a.m–and trumping other health-food stocks today.� Annie’s Homegrown (BNNY) has ticked up 0.4% to $49.61, Boulder Brands (BDBD) has risen 0.6% to $15.96 and Whitewave Foods (WWAV) has dropped 1.3% to� $18.93.
Top 10 Net Payout Yield Companies To Own For 2014: Sa Sa International Holdings Ltd (SAXJF)
Sa Sa International Holdings Limited is an investment holding company. The Company�� subsidiaries are principally engaged in the retailing and wholesaling of cosmetic products. Its business covers Hong Kong and Macau, Mainland China, Taiwan, Singapore, and Malaysia. The Company operates in two segments: retail segment, engaged in the operation of cosmetics specialty stores, which offer a variety of products from over 600 beauty brands, covering a wide of products from skin care, fragrance, make-up, body care and hair care to health foods, and brand management segment, engaged in the management of over 100 beauty brands. It also offers round-the-clock online shopping services along with product and corporate information through its e-commerce platform, sasa.com. The Company�� subsidiaries include Alibaster Management Limited, Base Sun Investment Limited, Cyber Colors Limited, Docile Company Limited and Elegance Trading (Shanghai) Company Limited, among others. Advisors' Opinion:- [By WWW.MARKETWATCH.COM]
HONG KONG (MarketWatch) -- Hong Kong stocks swung between small gains and losses early Thursday after hitting a seven-month high in the previous session, with the Hang Seng Index (HK:HSI) down less than 0.1%. Most mainland Chinese property developers outperformed the markets, with Guangzhou R&F Properties Co. (HK:2777) (GZUHF) rallying 3.4%, after the company reported a 44% month-on-month jump in sales for June. Shimao Property Holdings Ltd. (HK:0813) (SIOPF) climbed 2.6%, and China Resources Land Ltd. (HK:1109) (CRBJF) rose 1.7%. However, several retailers were weak, as Want Want China Holdings Ltd. (HK:0151) (WWNTF) , the country's top food and beverage maker, declined 2%. Hong Kong-based cosmetics brand Sa Sa International Holdings (HK:0178) (SAXJF) fell 1.6%, with a decline in Chinese June non-manufacturing data helping weigh on some retailers. Over on the Chinese mainland, the Shanghai Composite Index (CN:SHCOMP) retreated 0.4%, pulling back from its highest close in two weeks.
Top 10 Net Payout Yield Companies To Own For 2014: Etfs Gold Trust (SGOL)
ETFS Gold Trust (the Trust) is an investment trust. The investment objective of the Trust is for the Shares to reflect the performance of the price of gold bullion, less the expenses of the Trust�� operations. The Trust holds gold bullion and issues ETFS Physical Swiss Gold Shares (the Shares) in exchange for deposits of gold and distributes gold in connection with redemption of Baskets. The sponsor of the Trust is ETF Securities USA LLC (the Sponsor). The trustee of the Trust is The Bank of New York Mellon and the custodian is JP Morgan Chase Bank N.A. Advisors' Opinion:- [By Peter Pham]
Although the Fed doubled its bond buying last September, the top gold exchange-traded funds, or ETFs, including SPDR Gold Shares (NYSEMKT: GLD ) , iShares Gold Trust (NYSEMKT: IAU ) , and ETFS Physical Swiss Gold Shares (NYSEMKT: SGOL ) , have dropped around 25% each over the last 12 months, which speaks to gold's extreme vulnerability to QE tapering. Even the mere mention of tapering seems to send gold into a tailspin, as seen with SPDR Gold Shares, which has plunged 24% year to date and also suffered massive losses with its physical holdings. Market Vectors Gold Miners ETF (NYSEMKT: GDX ) has suffered a massive drop of 48% so far in 2013, making it one of the worst-performing ETFs this year.
Top 10 Net Payout Yield Companies To Own For 2014: Cardinal Health Inc. (CAH)
Cardinal Health, Inc. operates as a healthcare solutions company that provides health care products and services. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, over-the-counter healthcare, specialty pharmaceutical, and consumer products to retail customers, hospitals, and alternate care providers in the United States and Puerto Rico. This segment also operates nuclear pharmacies and cyclotron facilities that prepare and deliver radiopharmaceuticals for use in nuclear imaging and other procedures in hospitals and clinics; offers third-party logistics support services; franchises retail pharmacies under the Medicine Shoppe and Medicap brands; and provides pharmacy and pharmaceutical repackaging services, as well as other services comprising distribution, inventory management, data/reporting, new product launch support, and contract and chargeback administration. The Medical segment distributes a range of medical, surgical, and laboratory products to hospitals, surgery centers, laboratories, physician offices, and other healthcare providers. This segment also develops, manufactures, and sources medical and surgical products, including sterile and non-sterile procedure kits; single-use surgical drapes, gowns, and apparel; exam and surgical gloves; and fluid suction and collection systems. Its medical and surgical products are sold directly or through third-party distributors in the United States, Canada, Europe, South America, and the Asia/Pacific region. The company was founded in 1979 and is headquartered in Dublin, Ohio.
Advisors' Opinion:- [By Dividend King]
Earnings per share for the last 12 months are $2.59, and these are expected to reach $2.81 in its next fiscal year (ending September 2012). These numbers place the shares on a trailing P/E ratio of 15.43, and a forward multiple of 12.30. Comparing the forward ratio to that of direct competitors Cardinal Health (CAH) and McKesson (MCK) Amerisource trades on a slightly higher rating, though not markedly so. Cardinal Health�� forward multiple is 11.99 and McKesson�� is 11.22.
Top 10 Net Payout Yield Companies To Own For 2014: Ark Restaurants Corp. (ARKR)
Ark Restaurants Corp., through its subsidiaries, engages in the ownership and operation of restaurants and bars, fast food concepts, and catering operations. As of October 2, 2010, it owned and operated 22 restaurants and bars, including 9 facilities located in New York City; 4 in Washington, D.C.; 5 in Las Vegas, Nevada; 2 in Atlantic City, New Jersey; 1 at the Foxwoods Resort Casino in Ledyard, Connecticut; and 1 in the Faneuil Hall Marketplace in Boston, Massachusetts, as well as had 29 fast food concepts and catering operations. The company was founded in 1983 and is based in New York, New York.
Advisors' Opinion:- [By Bram de Haas]
Ark Restaurants Corp (ARKR) owns and operates 19 restaurants and bars, 22 fast food concepts and catering operations in the USA. This is a short article outlining why they are an interesting company to put on the buy list. It needs to be said, this is not a chain that can roll out their concept or brand nationwide and enjoy terrific growth of their franchise. They chose not to build up brands and instead operate under trade names that suit the unique locations they prefer. The reason that I want to highlight this small company is that in recent years they have faced numerous challenges and adversity (aside from those posed by the general economy) and it's possible they have dealt with the majority, and free cash flow will enjoy a significant uptick in the next two years.
Top 10 Net Payout Yield Companies To Own For 2014: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By James E. Brumley]
At first glance, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) doesn't look like anything particularly trade-worthy. The stock's now where it was in late October, and where it was in late September, and even where it was in late June. In other words, though RNN has been much higher and much lower than its current price of $0.46 over the course of the past several months, it doesn't look like it's going anywhere - on a net basis - anytime.
- [By John Udovich]
So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.
If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.
Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.
Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Net Payout Yield Companies To Own For 2014: Schweitzer-Mauduit International Inc.(SWM)
Schweitzer-Mauduit International, Inc. manufactures and sells paper and reconstituted tobacco products to the tobacco industry, as well as specialized paper products for use in various applications. It operates in two segments, Paper and Reconstituted Tobacco. The Paper segment primarily produces cigarette papers, such as lower ignition propensity papers, plug wrap papers, and base tipping papers to cigarette manufacturers that use to wrap various parts of a cigarette. It also offers commercial and industrial products, including lightweight printing and writing papers, battery separator papers, drinking straw wraps, filter papers, and other specialized papers to converters and other end-users or brokers. The Reconstituted Tobacco segment produces and sells reconstituted tobacco leaf, and wrapper and binder products to cigarette and cigar manufacturers. The company sells its products directly to customers in approximately 90 countries. Schweitzer-Mauduit International, Inc. was founded in 1995 and is headquartered in Alpharetta, Georgia.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Schweitzer-Mauduit International (NYSE: SWM ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment